Non-invasive Phrenic Nerve Stimulation in ARDS Patient
Launched by SOUTHEAST UNIVERSITY, CHINA · Aug 25, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with Acute Respiratory Distress Syndrome (ARDS) who are on mechanical ventilation. The goal is to see if a technique called non-invasive phrenic nerve stimulation can help improve the function of the diaphragm, the muscle that helps us breathe. When patients are on a ventilator for a long time, their diaphragm can weaken, which can lead to more serious health issues and longer hospital stays. By stimulating the phrenic nerve, researchers hope to encourage better diaphragm activity, potentially leading to improved recovery outcomes for patients with ARDS.
To be eligible for this trial, participants must be adults receiving controlled mechanical ventilation for ARDS, and they should have been intubated (having a breathing tube inserted) for less than 48 hours. However, certain individuals may not qualify, such as those with specific neurological conditions, paralysis of the phrenic nerve, or certain medical devices implanted in their bodies. If someone decides to participate, they can expect to receive this innovative treatment while being closely monitored by the medical team. This trial is currently recruiting participants, and anyone interested should discuss it with their healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult ARDS patients undergoing controlled mechanical ventilation
- • 2. The duration of endotracheal intubation \< 48 hrs
- Exclusion Criteria:
- • 1. Neurological condition affecting motor neuron or muscle (e.g. ALS)
- • 2. Paralysis of the phrenic nerve
- • 3. Proven or suspected spinal cord injury
- • 4. Conditions that limit diaphragm movement
- • 5. Patients with Implanted cardiac support systems (pacemaker, implanted defibrillator)
- • 6. Patients with implanted medical pumps
- • 7. Pregnancy
- • 8. Patients with skin lesions, infections or strictures in throat/neck area
- • 9. Patients with metallic implants
- • 10. Refusal to sign informed consent
About Southeast University, China
Southeast University, located in Nanjing, China, is a prestigious institution renowned for its commitment to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university leverages its robust academic resources and state-of-the-art facilities to conduct clinical trials that aim to address pressing healthcare challenges. Southeast University actively engages in partnerships with healthcare organizations and industry leaders to facilitate cutting-edge research, enhance patient outcomes, and contribute to the global medical community. Through its dedicated focus on ethical standards and scientific rigor, Southeast University is poised to make significant contributions to the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
ling liu, phD
Principal Investigator
Zhongda Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported